Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;16(4):273-284.
doi: 10.1038/nrd.2016.253. Epub 2017 Feb 17.

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Affiliations
Review

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Avi Ashkenazi et al. Nat Rev Drug Discov. 2017 Apr.

Abstract

Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals. In cancer, apoptosis evasion through dysregulation of specific BCL-2 family genes is a recurring event; accordingly, selective inhibition of specific anti-apoptotic BCL-2 family proteins represents an exciting therapeutic opportunity. A combination of nuclear magnetic resonance (NMR)-based screening and structure-based drug design has yielded the first bona fide BCL-2 homology 3 (BH3) mimetics, including the BCL-2 and BCL-XL dual antagonist navitoclax, which is the first BCL-2 family inhibitor to show efficacy in patients with cancer. Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. Recent advances have also been made in the development of potent and selective inhibitors of BCL-XL and myeloid cell leukaemia 1 (MCL1), which are additional BCL-2 family members with established anti-apoptotic roles in cancer. Here we review the latest progress in direct and selective targeting of BCL-2 family proteins for cancer therapy.

PubMed Disclaimer

References

    1. Cancer Cell. 2006 Nov;10(5):375-88 - PubMed
    1. Oncogene. 2011 Apr 21;30(16):1963-8 - PubMed
    1. Cancer Res. 2007 Feb 1;67(3):1176-83 - PubMed
    1. Nat Med. 2013 Feb;19(2):202-8 - PubMed
    1. Trends Cell Biol. 2013 Jan;23(1):22-9 - PubMed

MeSH terms

Substances